A North Carolina overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
More than one in three adults in North Carolina now live with obesity. The state's adult obesity rate reached 34.5% in 2024 (34.48% crude prevalence), according to the CDC's Behavioral Risk Factor Surveillance System — the most recent year in an unbroken data series that has tracked North Carolina every single year since 2011, when the rate stood at 29.1% 12. That's a 5.4-percentage-point climb over thirteen straight years of measurement, and as of the 2024 release, North Carolina's rate has moved past the national rate for the same year: 34.5% here versus 33.1% nationally 1. Counted alongside adults classified as overweight (34.8%), 69.3% of North Carolina adults — more than two out of every three — now fall above a healthy weight range 1.
North Carolina has also grown quickly over the same period this data covers. The state's population climbed from just under 10.45 million residents at the start of the decade to 11,046,024 as of the Census Bureau's Vintage 2024 estimate 3. A state adding residents while more than a third of its adults live with obesity means the number of North Carolinians who stand to benefit from effective, affordable weight-loss care keeps growing too — it isn't a shrinking problem in a shrinking state.
For the many North Carolinians enrolled in Medicaid, GLP-1 medications prescribed for weight loss are not a covered benefit — and that isn't a recent change. NC Medicaid's Outpatient Pharmacy Program, governed by Clinical Coverage Policy No. 9 (last amended July 15, 2024), categorically excludes "weight loss and weight gain drugs" from the pharmacy benefit under Section 4.2.1(i) and Attachment F, item 17 45. The state added this exclusion on May 1, 2006, "in compliance with mandated legislation," and has not reversed it in the eighteen years since — including in this year's amendment of the policy 4.
That doesn't mean GLP-1s are invisible to NC Medicaid. Semaglutide, tirzepatide, and other GLP-1 receptor agonists do appear on the program's prior-authorization drug list (Attachment K). But coverage there is gated on the drug having an FDA-approved or medically accepted indication for the diagnosis being treated (Section 3.2.1(a)) — for these drugs, that means type 2 diabetes, not obesity 4. In practice, a GLP-1 prescribed specifically for weight loss has no NC Medicaid coverage pathway right now, prior authorization or not. North Carolina has not opted, as a small number of other states have, to extend Medicaid pharmacy coverage to anti-obesity medications.
Outside of Medicaid, the price of GLP-1 care through Astra doesn't change by ZIP code or by city. Astra's semaglutide plan runs $68 a month, billed at $816 for a 12-month plan; its tirzepatide plan runs $118 a month, billed at $1,416 for a 12-month plan. That is the price whether a patient signs up from Asheville, Durham, Fayetteville, Wilmington, or any other North Carolina address — Astra prices its care nationally, not locally, so living outside a major metro doesn't mean paying more.
North Carolina regulates who can prescribe medications like semaglutide and tirzepatide through telehealth via the North Carolina Medical Board (ncmedboard.org), the licensing body for physicians and physician associates practicing in the state 6. Because prescribing rules run through each state's own medical board rather than a single national standard, Astra licenses its clinicians state by state and requires them to meet North Carolina's specific requirements for establishing a valid patient relationship and prescribing remotely. We're still finalizing the citation for a North Carolina Medical Board rule specific to telehealth GLP-1 prescribing — check back here for the update, or see the Board's site directly in the meantime.
Obesity prevalence, Medicaid's practical reach, and specialist access all look different depending on which North Carolina city you're standing in — and that's the level city data can actually speak to. Astra has published dedicated local pages, each pulling city-specific CDC, Census, and clinic pricing data, for four of North Carolina's metro markets: Asheville, Durham, Fayetteville, and Wilmington. More North Carolina cities are being added to this list.
Methodology and scope: the 34.5% obesity figure is crude prevalence, not age-adjusted, consistent with how BRFSS reports this indicator for this geography. HPSA designations and ACS uninsured-rate and median-household-income figures are deferred to those child city pages and intentionally not included at the state level; no city-level clinic pricing, obesity, or Census data was pulled in this state-level pass.
Astra is licensed to treat patients in all 50 states, North Carolina included — smaller cities and rural counties alike, not only the four metros with their own pages.
Astra treats patients in North Carolina through state-licensed physicians.
Asheville, Durham, Fayetteville, and Wilmington pages carry city-specific CDC, Census, and clinic pricing data.
No. NC Medicaid's Outpatient Pharmacy Program (Clinical Coverage Policy No. 9, amended July 15, 2024) categorically excludes weight-loss and weight-gain drugs from coverage under Section 4.2.1(i) and Attachment F — an exclusion in place since 2006. GLP-1 receptor agonists do appear on the state's prior-authorization drug list, but only for their FDA-approved indication, type 2 diabetes — not for obesity. There is currently no NC Medicaid pathway to GLP-1 coverage for weight loss.
No — and we're not going to pretend otherwise. Astra prices its semaglutide and tirzepatide plans the same nationally: $68 a month and $118 a month on 12-month plans ($816 and $1,416 billed annually), whether a patient is in Charlotte, Asheville, or anywhere else in the state. There's no North Carolina discount and no North Carolina markup — the price is the price everywhere Astra operates.
34.5% as of 2024, per the CDC's Behavioral Risk Factor Surveillance System (crude prevalence). That's up from 29.1% in 2011, and it now sits above the 2024 national rate of 33.1%.
Yes. Astra is licensed to provide GLP-1 care by telehealth to patients in all 50 states, including North Carolina, through visits with a clinician licensed in the state.
All of North Carolina. Astra's telehealth model means where you live within the state doesn't limit access to care. Dedicated local pages are already live for Asheville, Durham, Fayetteville, and Wilmington, with more North Carolina cities being added over time.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.